Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
List view / Grid view
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
1 October 2012 | By Merck
New data from Phase III studies...
1 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals has installed a fast track process transfer...
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
1 October 2012 | By Sanofi
Sanofi is pleased to announce the appointment of Dr. Paul Chew...
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
1 October 2012 | By BASF
As of October 1, Scott Thomson will assume the role of Senior Vice President...
28 September 2012 | By Bristol-Myers Squibb Company
Frances Heller will join as Senior VP, Business Development, on October 1...
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
27 September 2012 | By CI Precision
Actelion Pharmaceuticals Ltd, has endorsed CI SADE weight sorters...
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
25 September 2012 | By Cisbio Bioassays
Cisbio Bioassays announces the launch of its epigenetics toolbox for use in drug discovery research...